AstraZeneca blockbuster Farxiga adds new heart indication to label
AstraZeneca said Tuesday that the FDA has approved AstraZeneca’s Farxiga (dapagliflozin), an oral SGLT2 inhibitor, for a label extension to reduce …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
